Опубликовать статью

Информационное партнерство

Инфоресурсы

Контакты

«

Vol. 15, Art. 66 (pp. 816-833)    |    2014       

»

Comparative analysis of epidemiological, etiopathogenic and clinical features of mycosis of skin and its appendages in hiv-infected patients with and without HAART

Filippova V.S., Raznatovsky K.I.

North-Western State Medical University named after I.I. Mechnikov, chair of dermatovenerology

Brief summary

The present study showed, that incidence of cutaneous mycoses and its appendages was significant less in HIV-infected patients with HAART (34,6%) compared to HIV-infected patients without HAART (66,3%), what indicates on effective use HAART to prophylaxis and treatment of mycoses. Oral candidiasis, especially pseudomembranous form, is important clinical market of failure of HAART and progression of HIV-infection. Cutaneous mycoses and its appendages, particularly tinea cruris, tinea corporis, oral candidiasis, in HIV-infected patients with HAART, who belonged to the group №1, probably were clinical manifestations of immune reconstitution inflammatory syndrome (IRIS).


Key words

HIV-infection, HAART, candidiasis, onychomycosis, tinea cruris, tinea corporis, tinea pedis.

Reference list

1) Ribalko V.O., Sobennikov V.S., Aitov K.A. Nepsihoticheskie psihicheskie rasstroistva i priverjennost k lecheniu visokoaktivnoi antiretrovirysnoi terapiei y VICh-inficirovannih. // Sibirskii medicinskii jyrnal-2013- №4- S. 10-15


2) Vinogradova T. N. i dr. VICh-infekciya v Sankt-Peterbyrge//Kazanskii medicinskii jyrnal. – 2011.-S. 269-272.


3) UNAIDS. Report on the global AIDS epidemic: Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO). – 2008. – P. 1–36.


4) Bhaskaran K., Hamouda O., Sannes M., et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population //The Journal of the American Medical Association. — 2008. — Vol. 300 (1). — P.51-59.


5) Dyachenko A. G., Dyachenko P. A., Gorobchenko E. N. Blesk i nisheta antiretrovirysnoi terapii VICh-infekcii. – 2013. -Tom 1. -№4-S.13


6) Shahgildyan V. I., Belyaeva V. V. Palliativnaya pomosh pri VICh/SPIDe //Rykovodstvo po okazaniu palliativnoi pomoshi ludyam, jivyshim s VICh. M. – 2007.


7) Tschachler E, Bergstresser PR, Sting G. HIV-related skin diseases. Lancet. 1996; 348:659–663.


8) Maski VICh-infekcii v klinike vnytrennih boleznei / I. P. Kaidashev, N. D. G erasimenko, V. V. G orbatenko i dr. // Ykr. terapevt. jyrn. 2007. — № 2. — S. 57–65.


9) Pyzanova O. G. Revmaticheskie maski VICh-infekcii // Vnytrіshnya medicina. — 2007.— № 4.— S. 45–52.


10) Rudrambika R. N. Clinico pathological study of cutaneous lesions in hiv positive patients. – 2010.


11) Shukhtin V. V. et al. MORPHO-FUNCTIONAL CHARACTERISTICS OF THE SKIN AND MUCOSA IN HIV-INFECTED PATIENTS. Morfofynkcionalnaya osobennost koji i slizistih y VICh-inficirovannih bolnih //Journal of Health Sciences (J of H Ss). – 2013. – T. 3. – №. 1. – S. 61-72.


12) Valle SL, Saxinger C, Ranki A, Antonen J, Suni J, Lähdevirta J, et al. Diversity of clinical spectrum of HTLV-III infection. Lancet 1985; 1: 301–304.


13) Azfar N. A. et al. Frequency of mucocutaneous manifestations in HIV positive Pakistani patients //Journal of Pakistan Association of Dermatologists. – 2011. – T. 21. – №. 3. – S. 149-153.


14) Ivanova U.A., Raidenko O.V. Klinicheskie osobennosti mikozov stop, kistei i onihomikozov y vich-inficirovannih pacientov. Problemi medicinskoi mikologii, 13 (2011), 4 (dekabr), 18-21


15) Gyayrgieva O.H., Gorshkova G.I.,Bogomolova T.S., Jivich M.B. Mikozi i mikozonositelstvo y VICh-inficirovannih bolnih //3-i Mejdynar. mikol. simp. «Patogenez, diagnostika i terapiya mikozov i mikogennoi allergii». Tez. dok. -SPb. 1995.-S.41.


16) Ramos-E-Silva M, Lima CM, Schechtman RC, et al. Superficial mycoses in immunodepressed patients (AIDS). Clin Dermatol 2010; 28: 217-25.


17) Gupta AK, Taborda P, Taborda V, et al. Epidemiology and prevalence of onychomycosis in HIV-positive individuals. Int J Dermatol 2000; 39: 746-53.


18) Szepietowski JC, Reich A; National Quality of Life in Dermatology Group. Stigmatisation in onychomycosis patients: a population-based study. Mycoses 2009; 52: 343-349.


19) Papyashvili M. N. Kliniko-epidemiologicheskii analiz VICh i opportynisticheskih infekcii. Algoritmi diagnostiki i prognozirovaniya // Immynopatologiya, immynologiya, allergologiya. —2002.— № 4.— S. 88–92.


20) Diagnostika VICh-infekcii/5. SPID a. Problemi ostautsya / L. L. Sidorova, N. N. Sidorova, N. I. Stefanuk i dr. // Therapia. — 2008.— № 2.— S. 58–62.


21) Procenko O. A. VICh-associirovannie porajeniya koji i slizistih obolochek //Mejdynarodnii medicinskii jyrnal. – 2009.-№3-S.106-110


22) Arifov S. S., Sabirov Y. U., Nabiev T. A. Dermatologicheskie znaki y bolnogo SPID om // Klin. dermatol. venerol. — 2005.— № 3.S.14–15